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Tonsillectomy is one of the most frequently performed surgical procedures in children. 1 It remains associated with a high morbidity related to postoperative nausea and vomiting (PONV), pain, risk of bleeding, and dehydration due to impaired oral intake. 2 In children undergoing ambulatory tonsillectomy, PONV and pain are responsible for a hospital readmission rate of 14%. 3 PONV is of multi-factorial origin, with a reported incidence ranging from 23% to 73%. 4 5 Post-tonsillectomy pain is also multi-factorial; it is more intense within the first three postoperative days, but can persist until day 10. 6 Steroids can have beneficial effects on post-tonsillectomy morbidity due to their anti-emetic and anti-inflammatory properties; however, there is still no consensus on whether they should be used routinely after tonsillectomy. The most studied steroid for this purpose is dexamethasone (DEX), which is inexpensive and largely devoid of side-effects.
A recent Cochrane meta-analysis concluded that 'a single i.v. dose of DEX is an effective, safe and inexpensive treatment for reducing morbidity from paediatric tonsillectomy'. 7 The general consensus among authors is that DEX must be administered at the induction of anaesthesia to be effective, but the optimal dose is still debated. The aim of the present study was to evaluate the efficacy of two single i.v. doses of DEX, 0.15 and 0.5 mg kg 21 , on the incidence of PONV, and on pain intensity after elective tonsillectomy in children.
Methods
The Institutional Ethics Committee approved this study, and informed parental written consent was obtained. One hundred and forty-seven patients, aged 2-8 yr, undergoing elective tonsillectomy with or without adenotonsillectomy, were included in this prospective randomized double-blind study (EUDRACT number: 2006-005789-38 3 After tracheal intubation, anaesthesia was maintained with sevoflurane in a mixture of nitrous oxide and oxygen (50/50). Tonsillectomy was performed using the dissection technique combined with electrocoagulation when judged necessary by the surgeon. At the end of surgery, subjects were extubated when awake and transferred to the post-anaesthesia care unit (PACU). Each subject was assessed by trained nurses on the PACU. PONV was defined as vomiting and/or retching without expulsion of gastric content and was treated with i.v. alizapride (1 mg kg 21 maximum every 8 h) followed, if necessary, by tropisetron (0.1 mg kg 21 maximum every 12 h). Pain was assessed using the Children's Hospital of Eastern Ontario Pain scale (CHEOPS). 8 If the CHEOPS score was .7, i.v. morphine was titrated with a bolus of 25 mg kg 21 that was repeated every 5 min when necessary. On the ward, pain assessment was performed using the CHEOPS for children aged 2-5 yr and the visual analogue scale (VAS) for children aged 6-8 yr. 9 Postoperative analgesia consisted of paracetamol (15 mg kg 21 ) every 6 h and, if necessary (CHEOP.7 or VAS≥3), tramadol (2 mg kg 21 ) every 8 h. All agents were given i.v. in the PACU and on the ward until the venous line was removed. Criteria for discharge from the PACU included full consciousness, adequate pain control (CHEOPS≤7), no bleeding, stable vital signs, and no vomiting for at least 1 h after the children were capable of ingesting ice cubes without significant pain or PONV.
The following parameters were observed and recorded: incidence of PONV and need for treatment (alizapride and tropisetron); postoperative pain in the PACU until discharge to the ward, in the evening after surgery, and on the following day before discharge from the hospital; time to discharge from the PACU; and incidence of surgical re-exploration for bleeding. On the second postoperative day, the incidence of PONV and pain severity were evaluated by a phone call to the parents. Assessment of postoperative pain was performed using the postoperative pain measure for parents (PPMP) scale. 10 Because three different scales were used to evaluate postoperative pain, analysis of pain severity was dichotomously assessed as the presence of significant pain (CHEOPS.7, VAS≥3, PPMP.6) or no significant pain.
Statistical and sample size analysis
The primary outcome variable of the present study was the incidence of PONV. Previous studies 3 4 11 12 reported an incidence of PONV of 60 (24%) and a reduction of this incidence by about 50% with DEX. Based on these data, the present study had to include a minimum of 42 subjects in each group to have a power of 0.8 and an a of 0.05. After testing for normal distribution (Kolmogorov -Smirnov test), the three groups were compared using the Kruskal-Wallis test and x 2 where appropriate. Data are presented as median (inter-quartiles) or percentages. Randomization allocation was broken only after the statistical analysis was finalized. A P-value of ,0.05 was considered significant.
Results
From September 2005 to June 2010, 648 children undergoing tonsillectomy with or without adenoidectomy were screened for participation in the study (Fig. 1) . A total of 147 children were enrolled, of which 13 were excluded because of missing data. There were thus 134 children in the final analysis. The patient characteristic and type of surgery did not differ in the three groups (Table 1) . Only one subject (in the placebo group) required surgical re-exploration for significant bleeding.
The time (in min) until discharge from the PACU was not different in the groups [reported as median (25-75% IQ): placebo: 120 (90 -180); DEX 0.15: 120 (90 -150); DEX 0.5: 120 (90-157); P¼0.464]. However, the incidence of PONV was significantly reduced in the DEX groups compared with the placebo group both during hospitalization and on postoperative day 2 (Fig. 2) . There was no difference in PONV incidence between the two DEX groups. The use of alizapride was also lower in the DEX group than in the placebo group (Table 2) . Only a few subjects received tropisetron: six in the placebo group, two in the DEX 0.15 group, and one in the DEX 0.5 group (P¼0.118) ( Table 2) .
Administration of DEX did not reduce the number of subjects receiving morphine (PACU) or tramadol on the ward (Table 2) During hospitalization, the incidence of significant pain did not differ between DEX groups and the placebo group (Fig. 3) . However, on postoperative day 2, the incidence of significant pain was significantly lower in the DEX groups, and there was no difference in the incidence between the two doses (Fig. 2) .
Discussion
The results of the present study indicate that of DEX significantly reduces morbidity after tonsillectomy. A single dose of DEX given at the induction of anaesthesia reduced the incidence of early and late PONV and improved pain scores on the second postoperative day. A dose of 0.5 mg kg 21 DEX did not appear to be more effective than a dose of 0.15 mg kg 21 , although the study was not powered for this endpoint. Several studies have evaluated the effects of DEX on PONV and pain after paediatric tonsillectomy. They often included a limited number of patients 13 -16 and/or did not use standardized anaesthetic techniques and rescue treatment protocols. 12 16 In addition, the results of the few randomized placebo-controlled studies that evaluated the effects of a single i.v. corticosteroid administration are conflicting, in that some studies showed a beneficial effect, while others did not. 4 anti-emetic effect remain largely unknown. A direct inhibition of prostaglandins, serotonin, or endorphin production has been postulated. 17 Although the anti-inflammatory effects of DEX are well known, their effects on postoperative pain remain a point of debate. 1 17 18 We observed an effect on pain only on the second postoperative day. Based on the pharmacokinetic profile of DEX, it is expected that its anti-inflammatory effects will appear several hours after its administration. Therefore, it is not surprising that the effect of DEX on postoperative pain was observed only on the second postoperative day. This could also explain why some studies failed to observe significant pain reduction with DEX in the immediate postoperative period. The optimal dosage of DEX is also a subject of debate. Gunter and colleagues 20 and Kim and colleagues 21 compared DEX doses ranging from 0.0625 to 1.0 mg kg 21 in paediatric tonsillectomy. They did not observe a dosedependent effect on the incidence of PONV and pain. Karaman and colleagues 19 compared the effects of two doses of DEX, 0.2 and 0.7 mg kg 21 , with a placebo group on PONV after tonsillectomy, and observed a reduction in the incidence of PONV in the groups receiving DEX with no difference between the two doses. Our results are in line with these reports. In most studies, administration of DEX is not associated with significant side-effects in children undergoing tonsillectomy. 7 Only one study reported a dose-related increase in the incidence of postoperative bleeding. 15 However, this study was quite small and bleeding was far outside the generally reported range of about 1%. Moreover, a recent study in 2788 children did not observe a dose-dependent elevation of postoperative haemorrhage with perioperative DEX administration (0.5 or 1.0 mg kg 21 ).
22
Our results should be interpreted within the context of the study design. We decided to administer DEX at the induction of anaesthesia as it was shown to be more efficacious than when administered at the end of the procedure. 23 We selected children between 2 and 8 yr of age in order to have a standardized anaesthetic technique based on mask induction with sevoflurane and nitrous oxide. Indeed, mask induction is often not well accepted in children older than 8 yr. Nausea is difficult to assess in children up to 5 yr old. Therefore, we defined PONV as vomiting and/or retching without expulsion of gastric content. We still kept the term PONV instead of the term POV (postoperative vomiting) which only relates to vomiting and omits retching which can be considered as a marker of nausea.
We assessed pain severity using three scoring systems. The CHEOPS score is a behavioural observational pain score that is mostly used to assess pain severity in young children but is also applicable to older children in the immediate postoperative period (i.e. when they are still not capable of scoring pain by a VAS). The incidence of PONV and severe pain on postoperative day 2 were evaluated by a phone call to each child's parents using the PPMP scale. This scale has been validated for evaluating postoperative pain in children by the parents. 10 All our subjects remained in the hospital up to postoperative day 1, which allowed for a better assessment of postoperative pain and PONV. 
Funding
Supported by a departmental grant.
